205 related articles for article (PubMed ID: 17125641)
1. Enzyme replacement therapy in a child with Gaucher disease.
Masood Y; Ali AS
J Coll Physicians Surg Pak; 2006 Dec; 16(12):786-8. PubMed ID: 17125641
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy in type I Gaucher disease.
Kay AC; Saven A; Garver P; Thurston DW; Rosenbloom BF; Beutler E
Trans Assoc Am Physicians; 1991; 104():258-64. PubMed ID: 1845151
[No Abstract] [Full Text] [Related]
3. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
[TBL] [Abstract][Full Text] [Related]
4. Hematologic response in type I Gaucher's disease after enzyme replacement therapy.
Parco S; Bruno G; Durighello M; Giorgini R; Simeone R; Bembi B
Haematologica; 1999 Apr; 84(4):376-7. PubMed ID: 10190956
[No Abstract] [Full Text] [Related]
5. Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy.
Mitrovic M; Sumarac Z; Antic D; Bogdanovic A; Elezovic I; Vukosavljevic D; Ignjatovic S; Majkic-Singh N; Suvajdzic N
Blood Cells Mol Dis; 2012 Jun; 49(1):58-9. PubMed ID: 22459893
[No Abstract] [Full Text] [Related]
6. [Gaucher's disease with D409H/D409H genotype. evolution with enzyme replacement therapy].
Castelló Girona F; Domínguez Luengo C; del Toro Riera M; Chabás Bergon A
An Esp Pediatr; 2001 Mar; 54(3):310-2. PubMed ID: 11262263
[TBL] [Abstract][Full Text] [Related]
7. Early access experience with VPRIV(®): recommendations for 'core data' collection.
Hughes DA; Al-Sayed M; Belmatoug N; Bodamer O; Böttcher T; Cappellini M; Cohen IJ; Eagleton T; Elstein D; Giraldo P; Jones S; Kaplinsky C; Lund A; Machaczka M; Mengel E; Pastores GM; Rosenbaum H; Sjo M; Tiling N; Tsaftaridis P; Zimran A; Weinreb N
Blood Cells Mol Dis; 2011 Aug; 47(2):140-2. PubMed ID: 21146428
[No Abstract] [Full Text] [Related]
8. Prospects for enzyme replacement therapy in Gaucher disease.
Brady RO; Barranger JA; Furbish FS; Stowens DW; Ginns EI
Prog Clin Biol Res; 1982; 95():669-80. PubMed ID: 7122643
[No Abstract] [Full Text] [Related]
9. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations.
Charrow J; Andersson HC; Kaplan P; Kolodny EH; Mistry P; Pastores G; Prakash-Cheng A; Rosenbloom BE; Scott CR; Wappner RS; Weinreb NJ
J Pediatr; 2004 Jan; 144(1):112-20. PubMed ID: 14722528
[No Abstract] [Full Text] [Related]
10. Enzyme-replacement therapy for Gaucher's disease.
N Engl J Med; 1991 Dec; 325(25):1809-11. PubMed ID: 1944489
[No Abstract] [Full Text] [Related]
11. Effect of velaglucerase alfa enzyme replacement therapy on red blood cell properties in Gaucher disease.
Franco M; Reihani N; Marin M; De Person M; Billette de Villemeur T; Rose C; Colin Y; Moussa F; Belmatoug N; Le Van Kim C
Am J Hematol; 2017 Sep; 92(9):E561-E563. PubMed ID: 28621801
[No Abstract] [Full Text] [Related]
12. Correction of neutrophil chemotaxis defect in patients with Gaucher disease by low-dose enzyme replacement therapy.
Zimran A; Abrahamov A; Aker M; Matzner Y
Am J Hematol; 1993 May; 43(1):69-71. PubMed ID: 8317468
[TBL] [Abstract][Full Text] [Related]
13. Type I Gaucher disease in children with and without enzyme therapy.
Dweck A; Abrahamov A; Hadas-Halpern I; Bdolach-Avram T; Zimran A; Elstein D
Pediatr Hematol Oncol; 2002 Sep; 19(6):389-97. PubMed ID: 12186361
[TBL] [Abstract][Full Text] [Related]
14. Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy.
Burrow TA; Cohen MB; Bokulic R; Deutsch G; Choudhary A; Falcone RA; Grabowski GA
J Pediatr; 2007 Feb; 150(2):202-6. PubMed ID: 17236903
[TBL] [Abstract][Full Text] [Related]
15. Velaglucerase (Vpriv) for Gaucher's disease.
Med Lett Drugs Ther; 2010 May; 52(1337):36. PubMed ID: 20508578
[No Abstract] [Full Text] [Related]
16. Dosage-response in the treatment of Gaucher disease by enzyme replacement therapy.
Beutler E
Blood Cells Mol Dis; 2000 Aug; 26(4):303-6. PubMed ID: 11042031
[No Abstract] [Full Text] [Related]
17. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
Nagral A; Mewawalla P; Jagadeesh S; Kabra M; Phadke SR; Verma IC; Puri RD; Gupta N; Kishnani PS; Mistry PK
Indian Pediatr; 2011 Oct; 48(10):779-84. PubMed ID: 22080680
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.
Choi JH; Lee BH; Ko JM; Sohn YB; Lee JS; Kim GH; Heo SH; Park JY; Kim YM; Kim JH; Yoo HW
J Korean Med Sci; 2015 Apr; 30(4):378-84. PubMed ID: 25829804
[TBL] [Abstract][Full Text] [Related]
19. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
[TBL] [Abstract][Full Text] [Related]
20. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy.
de Fost M; van Noesel CJ; Aerts JM; Maas M; Pöll RG; Hollak CE
Haematologica; 2008 Jul; 93(7):1119-20. PubMed ID: 18519519
[No Abstract] [Full Text] [Related]
[Next] [New Search]
